Colette Kress sold $7.3M of NVDA
EVP & Chief Financial Officer at NVIDIA CORP. 50,500 shares at an average of $144.21, traded Jun 20, 2025, filed Jun 23, 2025.
Score components
- +22RoleCFO
- +25Trade size$7.3M at market
- 0Share of holdings soldSold 1.7% of holdings
- +15Cluster7 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +18.5%, 3m +27.4%, 6m +27.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001045810-25-000140, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 18, 2025 | FTax withholding Common10b5-1 | -43,099 | $144.12 | $6.2M | 3,042,666 | Jun 23, 2025 |
| Jun 20, 2025 | SOpen-market sale Common10b5-1 | -9,340 | $143.54 | $1.3M | 3,033,326 | Jun 23, 2025 |
| Jun 20, 2025 | SOpen-market sale Common10b5-1 | -14,578 | $144.04 | $2.1M | 3,018,748 | Jun 23, 2025 |
| Jun 20, 2025 | SOpen-market sale Common10b5-1 | -5,043 | $145.41 | $733k | 3,013,705 | Jun 23, 2025 |
| Jun 20, 2025 | SOpen-market sale Common10b5-1 | -1,539 | $145.90 | $225k | 3,012,166 | Jun 23, 2025 |
| Jun 20, 2025 | SOpen-market sale Commonindirect: By Trust10b5-1 | -3,051 | $143.55 | $438k | 180,009 | Jun 23, 2025 |
| Jun 20, 2025 | SOpen-market sale Commonindirect: By Trust10b5-1 | -4,797 | $144.04 | $691k | 175,212 | Jun 23, 2025 |
| Jun 20, 2025 | SOpen-market sale Commonindirect: By Trust10b5-1 | -1,662 | $145.41 | $242k | 173,550 | Jun 23, 2025 |
| Jun 20, 2025 | SOpen-market sale Commonindirect: By Trust10b5-1 | -490 | $145.90 | $71k | 173,060 | Jun 23, 2025 |
| Jun 20, 2025 | SOpen-market sale Commonindirect: By Limited Liability Company10b5-1 | -3,020 | $143.55 | $434k | 809,914 | Jun 23, 2025 |
| Jun 20, 2025 | SOpen-market sale Commonindirect: By Limited Liability Company10b5-1 | -4,839 | $144.04 | $697k | 805,075 | Jun 23, 2025 |
| Jun 20, 2025 | SOpen-market sale Commonindirect: By Limited Liability Company10b5-1 | -1,699 | $145.41 | $247k | 803,376 | Jun 23, 2025 |
| Jun 20, 2025 | SOpen-market sale Commonindirect: By Limited Liability Company10b5-1 | -442 | $145.91 | $64k | 802,934 | Jun 23, 2025 |
Related signals
Other insiders at NVIDIA CORP and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 35Weak | NVIDIA CORP | Tim Teter EVP, General Counsel and Sec | $6.8M 30,460 shares | -1% | |
| 75Notable | NVIDIA CORP | Mark A Stevens director | $300M 1,366,000 shares | -58% | |
| 42Moderate | NVIDIA CORP | Colette Kress EVP & Chief Financial Officer | $7.6M 34,918 shares | -4% | |
| 65Notable | NVIDIA CORP | Mark A Stevens director | $236M 1,022,239 shares | -30% | |
| 58Moderate | NVIDIA CORP | Mark A Stevens director | $411M 1,848,501 shares | -35% | |
| 28Weak | NVIDIA CORP | Tim Teter EVP, General Counsel and Sec | $6.5M 30,000 shares | -1% | |
| 45Moderate | NVDAsell NVIDIA CORP | Mark A Stevens director | $186M 885,000 shares | -15% | |
| 60Notable | NVIDIA CORP | Stephen C Neal director | $3.3M 15,500 shares | -12% | |
| 60Notable | NVIDIA CORP | Mark A Stevens director | $221M 1,000,000 shares | -14% | |
| 21Weak | NVIDIA CORP | John Dabiri director | $134k 625 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.